The prevention and treatment of sepsis: Is interleukin-6 a drug target or a drug?

Critical Care Medicine

Volumn 34, Issue 3, 2006, Pages 919-921

  Fink, Mitchell P ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

Critical illness; Interleukin 6; Sepsis

Indexed keywords

CARDIOTROPHIN 1; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 6; LEUKEMIA INHIBITORY FACTOR; MITOGEN ACTIVATED PROTEIN KINASE; MONOCLONAL ANTIBODY; STAT PROTEIN; TUMOR NECROSIS FACTOR ALPHA;

CHROMOSOME 7; DIMERIZATION; DNA BINDING; DRUG EFFECT; DRUG TARGETING; EDITORIAL; ENDOTHELIUM CELL; ENTEROPATHY; GLIA CELL; HUMAN; IMMUNE SYSTEM; MACROPHAGE; NONHUMAN; PRIORITY JOURNAL; PROPHYLAXIS; PROTEIN BINDING; PROTEIN PHOSPHORYLATION; PROTEIN SECRETION; REPRODUCIBILITY; SEPSIS; SIGNAL TRANSDUCTION; TRANSACTIVATION;

ANIMALS; APOPTOSIS; CROSS INFECTION; DISEASE SUSCEPTIBILITY; INTERLEUKIN-6; RECOMBINANT PROTEINS; SEPSIS; SHOCK, HEMORRHAGIC;

EID: 33644588309     PISSN: 00903493     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.CCM.0000203108.60429.DF     Document Type: Editorial

References (38)

1. Papanicolaou DA, Wilder RL, Manolagas SC, et al: The pathophysiologic roles of interleukin-6 in human disease. Ann Intern Med 1998; 128:127-137
2. Heinrich PC, Behrmann I, Haas S, et al: Principles of interleukin (IL)-6-type cytokine signalling and its regulation. Biochem J 2003; 374(Pt 1):1-20
3. Frost RA, Lang CH: Skeletal muscle cytokines: Regulation by pathogen-associated molecules and catabolic hormones. Curr Opin Clin Nutr Metab Care 2005; 8:255-263
4. Yu YH, Ginsberg HN: Adipocyte signaling and lipid homeostasis: Sequelae of insulin-resistant adipose tissue. Circ Res 2005; 96: 1042-1052
5. Jirik FR, Podor TJ, Hirano T, et al: Bacterial lipopolysaccharide and inflammatory mediators augment IL-6 secretion by human endothelial cells. J Immunol 1989; 142:144-147
6. Hungress ES, Luo GJ, Pritts TA, et al: Transcription factors C/EBP-beta and -delta regulate IL-6 production in IL-1beta-stimulated human enterocytes. J Cell Physiol 2002; 192: 64-70
7. Tsigos C, Papanicolaou DA, Defensor R, et al: Dose-effects of recombinant human interleukin-6 on pituitary hormone secretion and energy expenditure. Neuroendocrinology 1997; 66:54-62
8. Bataille R, Klein B: C-reactive protein levels as a direct indicator of interleukin-6 levels in humans in vivo. Arthritis Rheum 1992; 35: 982-984
9. Banks RE, Forbes MA, Storr M, et al: The acute phase protein response in patients receiving subcutaneous IL-6. Clin Exp Immunol 1995; 102:217-223
10. Spath-Schwalbe E, Hansen K, Schmidt F, et al: Acute effects of recombinant human interleukin-6 on endocrine and central nervous sleep functions in healthy men. J Clin Endocrinol Metab 1998; 83:1573-1579
11. Tsigos C, Papanicolaou DA, Kyrou I, et al: Dose-dependent effects of recombinant human interleukin-6 on glucose regulation. J Clin Endocrinol Metab 1997; 82:4167-4170
12. Klover PJ, Zimmers TA, Koniaris LG, et al: Chronic exposure to interleukin-6 causes hepatic insulin resistance in mice. Diabetes 2003; 52:2784-2789
13. Janssen SP, Gayan-Ramirez G, Van den Bergh A, et al: Interleukin-6 causes myocardial failure and skeletal muscle atrophy in rats. Circulation 2005; 111:996-1005
14. Starkie R, Ostrowski SR, Jauffred S, et al: Exercise and IL-6 infusion inhibit endotoxin-induced TNF-alpha production in humans. FASEB J 2003; 17:884-886
15. Patel RT, Deen KI, Youngs D, et al: Interleukin 6 is a prognostic indicator of outcome in severe intra-abdominal sepsis. Br J Surg 1994; 81:1306-1308
16. Calandra T, Gerain J, Heumann D, et al: High circulating levels of interleukin-6 in patients with septic shock: Evolution during sepsis, prognostic value, and interplay with other cytokines. The Swiss-Dutch J5 Immunoglobulin Study Group. Am J Med 1991; 91:23-29
17. Groeneveld AB, Tacx AN, Bossink AW, et al: Circulating inflammatory mediators predict shock and mortality in febrile patients with microbial infection. Clin Immunol 2003; 106:106-115
18. Reinhart K, Weigand-Lohnert C, Grimminger F, et al: Assessment of the safety and efficacy of the monoclonal anti-tumor necrosis factor antibody-fragment, MAK 195F, in patients with sepsis and septic shock: A multicenter, randomized, placebo-controlled, dose-ranging study. Crit Care Med 1996; 24: 733-742
19. Casey LC, Balk RA, Bone RC: Plasma cytokine and endotoxin levels correlate with survival in patients with the sepsis syndrome. Ann Intern Med 1993; 119:771-778
20. Riedemann NC, Neff TA, Guo RF, et al: Protective effects of IL-6 blockade in sepsis are linked to reduced c5a receptor expression. J Immunol 2003; 170:503-507
21. Gennari R, Alexander JW: Anti-interleukin-6 antibody treatment improves survival during gut-derived sepsis in time-dependent manner by enhancing host defense. Crit Care Med 1995; 23:1945-1953
22. Vyas D, Javadi P, Dipasco PJ, et al: Early antibiotic administration but not antibody therapy directed against IL-6 improves survival in septic mice predicted to die on basis of high IL-6 levels. Am J Physiol Regul Integr Comp Physiol 2005; 289:R1048-R1053
23. Leon LR, White AA, Kluger MJ: Role of IL-6 and TNF in thermoregulation and survival during sepsis in mice. Am J Physiol 1998; 275:R269-R277
24. Remick DG, Bolgos G, Copeland S, et al: Role of interleukin-6 in mortality from and physiologic response to sepsis. Infect Immun 2005; 73:2751-2757
25. Wang Q, Fang CH, Hasselgren PO: Intestinal permeability is reduced and IL-10 levels are increased in septic IL-6 knockout mice. Am J Physiol 2001; 281:R1013-R1023
26. Dalrymple SA, Slattery R, Aud DM, et al: Interleukin-6 is required for a protective immune response to systemic Escherichia coli infection. Infect Immun 1996; 64:3231-3235
27. Dalrymple SA, Lucian LA, Slattery R, et al: Interleukin-6-deficient mice are highly susceptible to Listeria monocytogenes infection: Correlation with inefficient neutrophilia. Infect Immun 1995; 63:2262-2268
28. Yang R, Han X, Uchiyama T, et al: IL-6 is essential for development of gut barrier dysfunction after hemorrhagic shock and resuscitation in mice. Am J Physiol Gastrointest Liver Physiol 2003; 285:G621-G629
29. Arikan AA, Yu B, Mastrangelo M-AA, et al: IL-6 treatment reverses apoptosis and blunts susceptibility to intraperitoneal bacterial challenge following hemorrhagic shock. Crit Care Med 2006; 34:771-777
30. Fink MP, Gardiner M, MacVittie TJ: Sublethal hemorrhage impairs the acute peritoneal inflammatory response in the rat. J Trauma 1985; 25:234-237
31. Bellido T, O'Brien CA, Roberson PK, et al: Transcriptional activation of the p21 (WAF1, CIP1, SDI1) gene by interleukin-6 type cytokines: A prerequisite for their pro-differentiating and anti-apoptotic effects on human osteoblastic cells. J Biol Chem 1998; 273: 21137-21144
32. Chen RH, Chang MC, Su YH, et al: Interleukin-6 inhibits transforming growth factorbeta-induced apoptosis through the phosphatidylinositol 3-kinase/Akt and signal transducers and activators of transcription 3 pathways. J Biol Chem 1999; 274: 23013-23019
33. Kovalovich K, Li W, DeAngelis R, et al: Interleukin-6 protects against Fas-mediated death by establishing a critical level of anti-apoptotic hepatic proteins FLIP, Bcl-2, and Bcl-xL. J Biol Chem 2001; 276: 26605-26613
34. Rollwagen FM, Li YY, Pacheco ND, et al: Microvascular effects of oral interleukin-6 on ischemia/reperfusion in the murine small intestine. Am J Pathol 2000; 156:1177-1182
35. Rollwagen FM, Yu ZY, Li YY, et al: IL-6 rescues enterocytes from hemorrhage induced apoptosis in vivo and in vitro by a bcl-2 mediated mechanism. Clin Immunol Immunopathol 1998; 89:205-213
36. Rollwagen FM, Li YY, Pacheco ND, et al: Systemic bacteraemia following hemorrhagic shock in mice: Alleviation with oral interleukin 6. Cytokine 1996; 8:121-129
37. Meng ZH, Dyer K, Billiar TR, et al: Distinct effects of systemic infusion of G-CSF vs. IL-6 on lung and liver inflammation and injury in hemorrhagic shock. Shock 2000; 14:41-48
38. Brundage SI, Zautke NA, Holcomb JB, et al: Interleukin-6 infusion blunts proinflammatory cytokine production without causing systematic toxicity in a swine model of uncontrolled hemorrhagic shock. J Trauma 2004; 57:970-977